

B

(¹ ;² , 010031)

~2010 11 2010 5
B 210
82.28% 83.33%, 54.72% 60%, 3 1
(P<0.05); (P<0.01)
B
B; ; ; A ;
R758.23;R758.22 1009-0959(2012)03-0444-02

To Observe the Clinical Effect of Eczema and Contact Dermatitis by Therapy Compound Polymyxin B Ointment Combination with Compound Flumetasone Ointment

Hao Hui-xia¹,Sha Na²

(¹The second hospital of Hohhot;²Hospital of Inner Mongolia,Hohhot 010031,China)

ABSTRACT Objective:To explore and observation the clinical effect of Eczema and Contact Dermatitis by therapy Compound Polymyxin B Ointment combination with Compound Flumetasone Ointment.**Methods:**Selecting 210 cases who went o to see doctor and diagnosis of Eczema and Contact Dermatitis in our hospital from May of 2010 to May of 2011,these patients were randomly divided into trial group and control group,using Compound Polymyxin B Ointment joint Compound Flumetasone Ointment in trial group and a separate Compound Flumetasone Ointment in control group.**Results:**The trial group total effective is significantly higher than that in control group (P<0.05),The trial group total effective is 82.28% and 83.33% no ineffectiveness;the control group total effective only 54.72% and 60% there cases ineffectiveness of Eczema and one case Contact Dermatitis;The time of cure of trial group significantly is lower than the control group (P<0.01).**Conclusion:**Compound Polymyxin B Ointment combination with Compound Flumetasone Ointment can reduce the time of cure and more significantly better than only Compound Flumetasone Ointment in the clinical effect.

KEY WORDS Compound Polymyxin B;Compound Flumetasone;Eczema;Contact Dermatitis;Effect

2010 5 1.3 [1,2]
B ()
210 , (/ /)
1 0() 1(
1.1) 2() 3()
2010 5 ~2011 5 210 , 1.4 [3]
10% : -)/ × 100% : /
B 1 =100%; : / 60%;
<2 \ : : / 20%; : /
1.2 +)× 100%
210 , 1.5
B (: , SPSS13.0
, :20090903) (($\bar{x} \pm s$) , t , ²
, :1012501) , , P<0.05
B 1:1 , 2
1 / ,7 1 , 2.1
2 , 14 210 , 121

* : , ;E-mil:418071780@qq.com

98 (/):
 66/55 51/47,
 ($\chi^2=0.14,P=0.71$); ($\pm s$): 65, 3
 (38± 5.23) (39± 4.98),
 (t=-0.13,P=0.89);
 79 (52 27) 42,
 53 (35 18)
 45, ($\chi^2=2.84,P=0.24$),

B B
 “ ” (TAO, Triple
 Antibioment Ointment),

2.2
 2.2.1 1
 B
 82.28%
 83.33%,
 3 1,
 54.72% 60%
 ()
 (P<0.05),
 B 1

1956 [7],
 [8], [3,9]
 B
 B
 3

1 ()				
(%)				
36	29	14	0	82.28
21	14	7	0	83.33
11	18	21	3	54.72
9	18	17	1	60.00

B
 [10]
 B

: $\chi^2=17.02,P<0.01$; $\chi^2=11.02,P=0.01$
 2.2.2

B

(P<0.01),
 3.5,
 B
 2 ()

B [J].
 ,2006;20(2):86-87
 [J].
 ,2006;20(4):253-254
 B
 [J]. ,2008;1(1):28-30

2.26± 1.24	6.3± 1.21	9.2± 2.27
3.35± 1.13	8.9± 1.47	12.7± 1.98

[M]. : .2009,599-604
 [J].
 ,2010;24(3):100-101

: ,t=3.76,P<0.01; ,t=3.47,P<0.01;
 ,t=2.84,P<0.01

.78 [J]. ,2010;8(11):11-12

2.3
 3
 (Allergic
 Skin Diseases)

[A]. :2008 .2008
 [C].2008
 Jones RN,Li Q,Kohut B,et al.Contemporary antimicrobial activity of triple
 antibiotic ointment:a multiphase study of recent clinical isolates in the United
 States and Australia[J].Diagn Microbio4>Tj1.04 0j0.976 0 TC9>Tj0.995 0 Td<09DD>Tj0.995 0 Td